NCT03819348: RAECDPT

Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi

Status unknown Last updated 28 January 2019

What this trial tests

trial testing the multiple programs of antifungal therapy for HIV-negative host in To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis in 1,200 participants. Status unknown.

Timeline

1 January 2003

Primary endpoint
30 December 2018

30 June 2019

Quick facts

Lead sponsor	Guangxi Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,200
Start date	1 January 2003
Primary completion	30 December 2018
Estimated completion	30 June 2019
Sites	1 location across China

Drugs / interventions tested

• the multiple programs of antifungal therapy for HIV-negative host

Conditions studied

• To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis — all drugs for To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis →
• To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections — all drugs for To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections →

Sponsor

Guangxi Medical University

Who can join

Eligibility, any sex, with To Investigate the Characteristics and Prognostic Factors of T. Marneffei Infections and the Causes of Misdiagnosis or To Study the Recurrence Indicators and Establish a Therapeutic Effect Evaluation System of T. Marneffei Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through a multi-center large-sample retrospective study, the epidemiological changes of TSM in Guangxi have been reviewed, its incidence trend was understood to attract the attention of clinicians; the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators. Improve the level of understanding and diagnosis and treatment of HIV-negative TSM in the whole area. A comprehensive efficacy evaluation system and standard treatment program was established to provide a basis for standardized treatment of TSM in HIV-negative hosts. The observational indicators included: 2-week all-cause mortality; 24-week all-cause mortality; clinical improvement time; level of decrease of fungus in the blood culture medium two weeks before treatment; recurrence; appearance of adverse drug reaction at the level 3 and above.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Talaromyces marneffei and nontuberculous mycobacteria co-infection in HIV-negative patients.
   Qiu Y, Huang J, Li Y, Zeng W, et al · · 2021 · cited 14× · PMID 34376749 · DOI 10.1038/s41598-021-95686-0
2. <i>Talaromyces marneffei</i> and <i>Burkholderia cepacia</i> Co-Infection in a HIV-Uninfected Patient with Anti-Interferon-γ Autoantibodies.
   Zeng W, Qiu Y, Tang M, Zhang H, et al · · 2021 · cited 3× · PMID 34140785 · DOI 10.2147/idr.s312042